Preventive administration of Rapaflo — Competitive Intelligence Brief

Preventive administration of Rapaflo (Preventive administration of Rapaflo) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1A adrenergic receptor antagonist. Area: Urology.

phase 3 Alpha-1A adrenergic receptor antagonist Alpha-1A adrenergic receptor Urology Small molecule

Target snapshot

Preventive administration of Rapaflo (Preventive administration of Rapaflo) — Sir Mortimer B. Davis - Jewish General Hospital. Rapaflo (silodosin) is an alpha-1A adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Preventive administration of Rapaflo TARGET	Preventive administration of Rapaflo	Sir Mortimer B. Davis - Jewish General Hospital	phase 3	Alpha-1A adrenergic receptor antagonist	Alpha-1A adrenergic receptor
Dexmedetomidine Hydrochloride	dexmedetomidine-hydrochloride	Pfizer	marketed	dexmedetomidine	Alpha-1A adrenergic receptor	1999-01-01
Levadil	DILEVALOL		marketed	dilevalol	Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Beta-1 adrenergic receptor	1990-01-01
Wellbutrin	bupropion	GSK (GlaxoSmithKline)	marketed	NDRI (Norepinephrine-dopamine reuptake inhibitor)	Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor	1985-12-30
Hylorel	GUANADREL	Pfizer	marketed	guanadrel	Alpha-1A adrenergic receptor	1982-01-01
Methoxamin	METHOXAMINE	GSK	marketed	methoxamine	Alpha-1A adrenergic receptor	1982-01-01
MAPROTILINE	MAPROTILINE		marketed	maprotiline	Alpha-1A adrenergic receptor	1980-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2032-01-04 — Dexmedetomidine Hydrochloride · 8242158 · US
• 2032-01-04 — Dexmedetomidine Hydrochloride · 9616049 · US
• 2032-01-04 — Dexmedetomidine Hydrochloride · 8648106 · US
• 2032-01-04 — Dexmedetomidine Hydrochloride · 9320712 · US
• 2032-01-04 — Dexmedetomidine Hydrochloride · 8455527 · US
• 2032-01-04 — Dexmedetomidine Hydrochloride · 10016396 · US
• 2032-01-04 — Dexmedetomidine Hydrochloride · 8338470 · US
• 2032-07-04 — Dexmedetomidine Hydrochloride · 8242158*PED · US
• 2032-07-04 — Dexmedetomidine Hydrochloride · 8648106*PED · US
• 2032-07-04 — Dexmedetomidine Hydrochloride · 8455527*PED · US
• 2032-07-04 — Dexmedetomidine Hydrochloride · 8338470*PED · US
• 2032-07-04 — Dexmedetomidine Hydrochloride · 9320712*PED · US
• 2032-07-04 — Dexmedetomidine Hydrochloride · 9616049*PED · US
• 2036-04-20 — Dexmedetomidine Hydrochloride · 9717796 · US
• 2036-04-20 — Dexmedetomidine Hydrochloride · 9649296 · US
• 2039-06-26 — Dexmedetomidine Hydrochloride · 11517524 · US
• 2039-06-26 — Dexmedetomidine Hydrochloride · 11497711 · US
• 2039-06-26 — Dexmedetomidine Hydrochloride · 10792246 · US
• 2039-06-26 — Dexmedetomidine Hydrochloride · 11478422 · US

Sponsor landscape (Alpha-1A adrenergic receptor antagonist class)

1. EMS · 1 drug in this class
2. GlaxoSmithKline · 1 drug in this class
3. Gundersen Lutheran Medical Foundation · 1 drug in this class
4. New York Prostate Institute · 1 drug in this class
5. Pierre Fabre Medicament · 1 drug in this class
6. Sir Mortimer B. Davis - Jewish General Hospital · 1 drug in this class